Daptomycin

Therapeutic

Lipopeptide antibiotic active against Gram-positive bacteria only.

Structural features

SMILES

CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=CC=CC=C2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O

Sequence

Dec-WnDTGXDaDGsXX

Molar mass

1620.693 g/mol

Constitutional members:

14

Natural amino acids

7

D-Amino acids

3

N-terminus

decanoyl

C-terminus

cycle

Cyclic

yes

Members/cycle

10

Bond to form cycle

head-to-side chain (Kyn-Tyr)

Lipidation

yes

Glycosylation

no

Route of administration

IV

Terminal half-life

8-9 hours (up to 28 hours in renal impairment)

Protein binding

90-93%

Absorption and Bioavailability

Generally exhibits linear and time-independent pharmacokinetics at a dosage of 4–12 mg/kg IV once every 24 hours. Steady-state trough serum concentrations are achieved by the third daily dose.

References